Low-dose extrapolation and dose-related transitions are paramount in the ongoing debate regarding the quantification of cancer risks for nongenotoxic carcinogens. Phenobarbital (PB) is a prototypical nongenotoxic carcinogen that activates the constitutive androstane receptor (CAR) resulting in rodent liver tumors. In this study, male and female CD-1 mice administered dietary PB at 0, 0.15, 1.5, 15, 75, or 150 mg/kg-day for 2 or 7 days to characterize multiple apical and molecular endpoints below, at (∼75 mg/kg-day), and above the carcinogenic dose level of PB and examine these responses using benchmark dose modeling. Linear toxicokinetics were observed for all doses. Increased liver weight, hepatocellular hypertrophy, and mitotic figures were seen at 75 and 150 mg/kg-day. CAR activation, based on Cyp2b qPCR and pentoxyresorufin dealkylase activity, occurred at doses ≥ 1.5 mg/kg-day. The no-observable transcriptional effect level for global gene expression was 15 mg/kg-day. At 2 days, several xenobiotic metabolism and cell protective pathways were activated at lower doses and to a greater degree in females. However, hepatocellular proliferation, quantified by bromodeoxyuridine immunohistochemistry, was the most sensitive indicator of PB exposure with female mice more sensitive than males, contrary to sex-specific differences in sensitivity to hepatocarcinogenesis. Taken together, the identification of lowdose cellular and molecular transitions in the subtumorigenic dose range aids the understanding of early key events in CAR-mediated hepatocarcinogenesis.
Phenobarbital (PB), the most widely used anticonvulsant in the world, is a well-established nongenotoxic rodent hepatocarcinogen (Lee, 2000) . PB is also one of the best-known activators of the constitutive androstane receptor (CAR), a nuclear receptor xenobiotic sensor that induces transcription of genes regulating phase I and II detoxification/transporter enzymes (Kodama and Negishi, 2006) . Through CAR activation, rodents treated with PB respond in most cases with elevated gene transcripts, enzyme activity, hepatocellular proliferation, and eventually proliferative liver lesions (Wei et al., 2000; Yamamoto et al., 2004) . Metabolic induction of Cyp2b10 is considered the prototypical gene response following PB exposure in mice (Ueda et al., 2002) . Cyp3a11 is also induced through CAR and possible cross-talk with the pregnane X receptor (PXR; Tien and Negishi, 2006) . The majority of CAR activators (including PB) act through an indirect, phosphorylation-dependent mechanism (Ding et al., 2006) .
The mode of action (MOA) and key events for PB-induced rodent liver tumors have been well studied and reviewed elsewhere (Cohen, 2010; Holsapple et al., 2006) . Non-DNAreactive rodent liver tumorigens can induce hepatic responses (enzyme induction and hypertrophy) and stimulate hepatocellular proliferation through receptor-mediated mechanisms that involve the aryl hydrocarbon receptor (AhR), CAR, PXR, and/or the peroxisome-proliferator-activated receptor alpha (PPAR␣). Indirect or nonreceptor-mediated mechanisms leading to rodent hepatocarcinogenesis can involve cytotoxicity, infection, metal overload, and/or increased apoptosis (Cohen, 2010) . Other mechanisms such as estrogen receptor activation, exposure to statins, and receptor-mediated cytotoxicity can also occur. Of these MOAs, the human relevance of enzyme induction through CAR, PXR, or PPAR␣ activation, exposure to statins, and increased apoptosis has been questioned (Holsapple et al., 2006) . The MOA for PB-induced rodent liver tumor formation was recently concluded to be qualitatively not plausible for the assess-426 GETER ET AL. ment of human cancer risk (Elcombe et al., 2014) . It was further noted that the hepatic effects of PB are dose-dependent and exhibit a threshold. In male CD-1 mice, the no-observable-effect level (NOEL) and tumorigenic dose was 10 and 75 mg/kg-day, respectively, after chronic dietary PB exposure (Whysner et al., 1996) . In male C57BL/10J mice, the NOEL and tumorigenic dose was 200 ppm (22 mg/kg-day) and 1000 ppm (113 mg/kgday), respectively, after chronic dietary PB exposure (Jones et al., 2009) . Corresponding estimates in female mice have not been reported.
In addition to dose, temporal progression of key events in the MOA has also been proposed (Elcombe et al., 2014) , but very few studies employing a multiple dose and time-course design in both sexes are available. Further, very few studies have investigated low-dose effects and dose-related transitions over time.
As most laboratory studies evaluated the tumorigenic dose, there is a compelling need for data at subtumorigenic doses to understand the molecular and mechanistic events and the sexspecific differences involved in CAR-mediated hepatotumorigenesis. Further, newer molecular technologies such as wholegenome transcriptional analysis now complement conventional bioassay endpoints such as histopathology, enzyme activity, and biochemical assays (Mahadevan et al., 2011; Waters and Yauk, 2007) . Similarly, benchmark dose (BMD) response methods have been employed since the 1980s to aid in low-dose quantitative risk assessment (Crump, 1984) , and these methods have since been adapted for microarray data and combined genelevel BMD estimates to facilitate mapping to cellular pathways (Thomas et al., , 2013 Yang et al., 2007) . In addition to identifying key events, another goal of MOA-based risk assessment is to obtain quantitative dose-response and time-course data on measurable parameters associated with those key events (Edwards and Preston, 2008) . This study was designed to evaluate the early dose and temporal pattern of molecular, cellular, biochemical, and phenotypic changes in male and female CD-1 mice exposed to sub-and tumorigenic dietary doses of PB. BMD-response modeling was then used to estimate low-dose potency, contrast between sexes, and characterize the concordance of early key events at multiple levels of biological organization thereby informing quantitative risk assessment of CARmediated hepatocarcinogenesis.
MATERIALS AND METHODS

Animals and treatment.
These studies were conducted using 6-week-old male and female (nulliparous and nonpregnant) Crl:CD1(ICR) mice from Charles River Laboratories, Inc. (Portage, MI). Animals were treated humanely with regard for alleviation of suffering, and housed under conditions of controlled temperature (22
• C ± 1 • C), humidity (40-70%), and light cycle (12 h, on at 6 am), and were given food and municipal water ad libitum. The in-life procedures were performed at The Dow Chemical Company, Toxicology and Environmental Research & Consulting (TERC), Midland, MI. The facility is accredited by the American Association for Accreditation of Laboratory Animal Care. In accordance with the U.S. Department of Agriculture animal welfare regulations, 9 CFR, Subchapter A, Parts 1-4, the animal care and use activities required for conduct of these studies, were reviewed and approved by the Institutional Animal Care and Use Committee.
Dietary test article preparation, analysis, and exposure. PB was delivered in the diet, which was prepared by serially diluting a concentrated test material-feed mixture with ground feed (LabDiet Certified Rodent Diet #5002, PMI Nutrition International, St Louis, MO). Premixes and diets were mixed prior to study initiation and prepared as a fixed percent of test material in the feed. Analytical confirmation of all dose levels, plus control and premix, were determined pre-exposure. Homogeneity of the test material-feed mixture was determined concurrent with dose confirmation using a solvent extraction method followed by liquid chromatography-mass spectrometry analysis. The concentration and homogeneity of PB in the diets were determined prior to animal exposure and found to be within acceptable ranges (data not shown) and stable in feed for over 14 days at the dietary levels used in this study. Exposures were conducted for 2 or 7 days. Based on the 5.2-and 38.7-fold induction in Cyp2b10 relative transcript levels at 50 and 100 mg/kg-day in a pilot study, the concentrations of dietary PB used in the main study were 0, 0.15, 1.5, 15, 75, and 150 mg/kg-day. Feed consumption was determined for all animals by weighing feed containers at the beginning and end of the respective exposure period. Test material intake was calculated upon completion of the study using test material concentrations in the feed, body weights, and measured feed consumption.
Osmotic pumps. One day prior to exposure, mice were implanted with mini-osmotic pumps (Model 2001; Alzet Corp., Palo Alto, CA) containing bromodeoxyuridine (BrdU). Mice were continuously infused with BrdU via the implanted osmotic pumps filled with a solution of 20 mg/ml BrdU in phosphatebuffered saline (pH 7.6) at a delivery rate of 1 l/h. Clinical data and pathology. Animals were not fasted overnight prior to blood collection. Blood samples were obtained from the orbital sinus following anesthesia with isoflurane/O 2 at necropsy. Serum parameters were measured using a Hitachi 912 Clinical Chemistry Analyzer (Roche Diagnostics, Indianapolis, IN). The concentrations of the following were measured: cholesterol, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and triglycerides (TGs).
Mice submitted for necropsy were weighed (with the implanted osmotic pump in situ), anesthetized by inhalation of isoflurane/O 2 , and blood samples obtained from the orbital sinus. The animals were then euthanized by decapitation. The osmotic pumps were removed, weighed, and the weights were subtracted from the body weights to determine the final body weight. The liver was excised, weighed, and the upper quarter of the left lateral liver lobe was processed in RNAlater for qPCR analysis. The upper middle quarter of the left lateral lobe was trimmed and preserved in neutral phosphate-buffered 10% formalin and used for histological examination and BrdU proliferation analysis. In addition, a 2-3 cm segment of the proximal duodenum was excised, flushed with fixative, and placed in the same fixative with the liver tissue for BrdU analysis to serve as a positive control for proliferation analysis. Oil Red O staining for lipid demonstration was conducted on frozen sections obtained from the lower middle quarter of the left lateral lobe. The lower quarter of the left lateral liver lobe and the lower portion of the medial liver lobe were flash frozen and stored at −80
• C for enzyme activity analysis. Three hematoxylin and eosin stained sections of the liver and one section of duodenum were histologically evaluated from each group. Liver histopathological lesions were recorded in all mice and severity was evaluated as very slight or slight (< 25% involvement of the tissue with no loss of function), moderate (up to 50% of the tissue with some loss of function), or severe (more than 50% of the tissue with significant dysfunction). No other tissues were used.
Hepatic gene expression. Liver samples preserved in
RNAlater from all exposure groups were used for RNA isolation. Total RNA was extracted using the Qiagen RNeasy kit following the manufacturer's protocol (Qiagen Inc., Valencia, CA). RNA quantity and quality were assessed by a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE) and Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA), respectively. Only samples with an OD 260/280 ratio greater than 1.8 and with clearly defined 28S and 18S bands were used for gene expression studies. Total RNA was treated with DNase enzyme to avoid DNA contamination. Gene expression studies were conducted with an Applied Biosystems 7500 fast real-time Polymerase Chain Reaction system (Applied Biosystems, Foster City, CA) using Applied Biosystems (ABI) TaqMan Gene Expression Assays.
TaqMan analysis of the following genes was investigated: (1) Cyp1a1 "AhR associated gene" [CYP1A1 in humans] ABI assay ID: Mm00487218 m1; (2) Cyp1a2 "AhR associated gene" [CYP1A2 in humans] ABI assay ID: Mm00487224 m1; (3) Cyp2b10 "CAR associated gene" [CYP2B6 in humans] ABI assay ID: Mm00456591 m1; (4) Cyp3a11 "PXR associated gene" [CYP3A4 in humans] ABI assay ID: Mm00731567 m1; (5) Cyp4a10 "PPAR␣ associated gene" [CYP4A11 in humans] ABI assay ID: Mm02601690 gH. "␤-actin" was used as the internal standard (ABI TaqMan ID: Mm00607939 s1). Data was analyzed (detailed in statistics section) by generation of cycling time (Ct) and delta Ct ( Ct) values for all genes. Each sample was analyzed in triplicate for the reference and target genes. No outliers were omitted. Amplification curves were processed using Sequence Detection Software 1.4 (ABI).
Affymetrix microarray hybridization and data analysis.
Gene expression analysis was conducted using Affymetrix Mouse Genome 430 2.0 GeneChip arrays (Affymetrix, Santa Clara, CA). This whole mouse genome array interrogates 34,000 variants and 39,000 transcripts from well-characterized mouse genes using 45,000 probe sets. Total RNA (4 g) for each sample was amplified and labeled by the Enzo BioArray RNA Amplification and Biotin labeling System (Enzo Life Sciences, Farmingdale, NY). For each array, 15 g of amplified biotin-cRNAs were fragmented and hybridized to the array for 16 h at 45
• C in a rotating hybridization oven using the Affymetrix eukaryotic target hybridization controls and protocol. Hybridized probe sets on the array were stained with streptavidin/phycoerythrin using a double-antibody staining procedure and washed using the EukGE-WS2v5 protocol of the Affymetrix fluidics station FS450 for antibody amplification. Arrays were scanned with an Affymetrix scanner 3000.
The raw signal intensities from each scan (.cel files) were imported into the gene expression analysis software Rosetta Resolver version 7.2 (Rosetta Inpharmatics, Kirkland, WA). This software was used to determine which probe sets in a treatment group differed from the control group. The scans were converted into profiles within this software and the data were normalized using Rosetta error model (Weng et al., 2006) . Principal Component Analysis (PCA) was applied at the profile level to examine within and across group similarity/dissimilarity. Statistically filtered sequences were identified using one-way ANOVA with a false discovery rate (Benjamini-Hochberg test) of p ≤ 0.05 for significance. Fold change for each sequence was computed for each calculated ratio, representative of a given sequence abundance.
Microsome isolation for in vitro enzyme activity assays.
Frozen liver samples were thawed on ice and homogenized using a Potter-Elvehjem apparatus. Microsomes were isolated using the method outlined by Guengerich (1982) . All centrifugation steps were carried out at 0
• C-5 • C and total microsomal protein levels were determined for individual animals using the Pierce bicinchoninic acid method (Pierce Chemical Co., Rockford, IL). Enzyme activity for Cyp1a was measured by examining the O-dealkylation of ethoxyresorufin (EROD), Cyp2b used pentoxyresorufin (PROD), and Cyp3a used benzyloxyresorufin (BROD). Activities were measured using a microplate fluorometric method (Kennedy and Jones, 1994) . Briefly, these methods involve the measurement of the in vitro O-dealkylation of 7-alkoxyresorufins to a highly fluorescent product, resorufin, by closely related microsomal mixed function oxidases (Burke and Mayer, 1983) .
Hepatocellular proliferation. Levels of hepatocyte Sphase DNA synthesis were determined using 5-bromo-2'-deoxyuridine (BrdU) immunohistochemistry for identification of BrdU incorporation into nuclear DNA (Eldridge et al., 1990) . At necropsy, sections of the liver were treated as detailed previously, processed by standard techniques, and mounted on glass slides. Tissues were stained for BrdU using the manufacturers' protocol (BD Biosciences, San Diego, CA) with modified heat-induced antigen retrieval. A small section of duodenum from each mouse was also processed as a control for confirming systemic incorporation of BrdU and for immunohistochemical staining. Using light microscopy, a labeling index was calculated and positive nuclei were scored as percentages based on 1000 hepatocytes in each of three hepatolobular zones: centrilobular, midzonal, and periportal regions. All BrdU slides were coded and read without knowledge of treatment.
Dose-response modeling of apical and transcriptional data. BMD-response analysis was conducted to estimate the dose at which specific genes, cellular pathways, and apical effects were altered above or below background (i.e., controls). BMD estimates for apical endpoints (BMD A ), which included liver weight, hepatocellular proliferation, and liver qPCR and enzyme activity, were conducted using BMD software version 2.4 with the benchmark response set to one control standard deviation from the control mean (BMD 1SD ) and included the lower 95% confidence limit (BMDL 1SD ; Davis et al., 2011; EPA, 2012a,b) . Best-fit model selection included consideration of the global goodness-of-fit p value (≥ 0.1), local scaled residual values of less than /2/, visual fit, and Akaike's Information Criterion (AIC is −2L + 2p, where L is the log-likelihood at the maximum likelihood estimates for p estimated parameters; Akaike, 1973) .
Transcriptional benchmark dose (BMD T ) analysis of the liver microarray data was conducted using BMDExpress version 1.4.1 Yang et al., 2007) with some modifications. Briefly, the estimated consumed dietary intake (mg/kgday) served as the dose metric and normalized linear signal intensities for all probe sets were fit as continuous data to the following five dose response models-Hill, linear, 2
• polynomial, 3
• polynomial, and power models. Each model was run assuming constant variance and the benchmark response factor was set to 1.349 the standard deviation in the control animals to estimate a BMD T with a 10% increase in tail area . For the best-fit model selection, a nested likelihood ratio test was performed on the linear and polynomial models. If the more complex model provided a significantly improved fit (p < 0.05), the more complex model was selected. The simpler model was selected if the more complex model did not provide a significantly improved fit (Posada and Buckley, 2004) . Similar to BMD A guidelines (EPA, 2012a), models with a global goodness-of-fit p value < 0.1 were excluded; p values of 1 indicate a perfect fit (i.e., the model's predicted response is identical to the observed response). To select the best globally fitting model with the least complexity, the AIC for the selected polynomial model was then compared with the AIC for the Hill and power models. The model with the lowest AIC was selected as the final model. In cases where the "k" slope parameter for the Hill model was out of bounds, the Hill model was excluded from the final selection. Probe sets with a BMD T value greater than the highest dose or a global goodness-of-fit p value < 0.1 were considered unacceptable fits and thus were excluded. Affymetrix probe sets were converted into unique genes based on their NCBI Entrez Gene ID and promiscuous probe sets that measured more than one gene were removed. In addition to the BMD T analysis, IPA (Ingenuity Pathway Analysis, Ingenuity Systems, www.ingenuity.com) was used to map the differentially expressed genes (DEGs) to canonical pathways to reveal biologic processes inherent in the significantly filtered gene lists. Then, the median BMD T and lower 95% confidence limit (BMDL T ) values from the genes represented in each pathway with an adequate statistical fit were used to summarize each pathway.
Statistics. Means and standard deviations were calculated for continuous data. Feed consumption, in-life body weight, terminal body weight, liver weight, relative liver weight, cholesterol, ALT, AST, enzyme activity, and hepatocellular proliferation were tested for homogeneity of variance and transformed if Bartlett's test was significant. Then the data were evaluated using a one-way analysis of variance followed by Dunnett's test (alpha = 0.05) when a statistically significant dose effect existed. TaqMan gene expression was quantified using the comparative Ct method ( Ct). The expression of the amount of target mRNA, normalized to an endogenous reference and relative to a calibrator, was reported as a fold change compared with control by the following formula: fold = 2 − Ct . To test for significant qPCR gene expression changes, a nonparametric Wilcoxon two-tailed, two-sample test was performed on Ct with alpha < 0.05 and a ≥ 1.5 fold change considered to be a significant change in gene expression (Yuan et al., 2006) . SAS software (SAS, Cary, NC) was used for the analyses.
RESULTS
In-Life Observations and Mean Test Compound Intake
All mice survived and no adverse treatment-related observations were made during the study. Feed consumption in treated groups was comparable to their respective controls at both time points. The time-weighted average consumed dose of PB at 2 days was 0, 0.137, 1.41, 14.1, 67.5, or 148 mg/kg-day for males and 0, 0.146, 2.37, 14.2, 62.8, or 134 mg/kg-day for females. The time-weighted average consumed dose of PB at 7 days was 0, 0.136, 1.32, 15.1, 68.5, or 137 mg/kg-day for males and 0, 0.138, 1.40, 14.1, 72.4, or 145 mg/kg-day for females. For perspective, a therapeutic dose of PB as an anticonvulsant in humans, cats, and dogs is 1-4 mg/kg-day (Merck, 2011) .
Plasma Kinetics in CD-1 Mice
Mean plasma concentrations of PB in mice after 2 and 7 days of dietary PB administration are shown in Figure 1 . Statistical
FIG. 1.
Lower plasma PB levels at 7 days compared with 2 days in both sexes demonstrate increased metabolic capacity.
analysis of the plasma concentrations showed no deviation from linearity at either time point (data not shown). At 0.15 and 1.5 mg/kg-day for both sexes and 15 mg/kg-day for males, plasma PB concentrations were comparable (<10% different) at 2 and 7 days. However, females at 15 mg/kg-day and both sexes at 75 and 150 mg/kg-day saw a marked (30-50%) decrease in plasma PB concentration on day 7 compared with day 2. For the high dose, plasma PB concentrations at 2 and 7 days were 1.5-and 1.6-fold higher in male than female mice, respectively.
Clinical Chemistry
Relative to controls, males given 75 and 150 mg/kg-day of PB for 2 days had a statistically significant increase in plasma ALT. Although there was no clear dose-dependent increase in ALT, the increased values at 75 and 150 mg/kg-day may have been related to the treatment-related necrosis of individual hepatocytes. Mice exposed to 150 mg/kg-day PB for 7 days had statistically decreased serum albumin levels compared with controls and males had statistically increased serum TGs. No statistically significant changes in serum cholesterol were observed at either 2 or 7 days.
Terminal Body and Liver Weights
Mean body and liver weights (absolute and relative to body weight) are given in Supplementary table 1. There were no statistically identified treatment-related differences in body weights of mice at any dose level compared with control animals throughout the study. Males and females given 150 mg/kgday PB for 2 days and 75 and 150 mg/kg-day for 7 days had treatment-related increases in mean absolute and relative liver weights (20-48%).
Histopathology Observations: Male
Three of four males given 15 mg/kg-day PB for 2 or 7 days exhibited very slight centrilobular/midzonal hepatocyte hypertrophy with altered tinctorial properties of the cytoplasm (increased eosinophilia; IE). Three of four males given 75 mg/kg-day for 2 days had slight and one had very slight centrilobular/midzonal hepatocyte hypertrophy with IE. All males given 75 and 150 mg/kg-day for 7 days had slight centrilobular/midzonal hepatocyte hypertrophy with IE. A dose-dependent increase in the incidence of hepatocyte mitotic figures was noted in male mice given 75 (2/4 mice) or 150 mg/kg-day (4/4 mice) PB for 2 days. At 7 days, 2/4 males given 75 or 150 mg/kg-day had increased hepatocyte mitotic figures. One male mouse (1/4) exposed to 15 mg/kg-day PB for 7 days had an increased number of hepatocytes in mitoses. Additional findings in males included a dose-dependent increase in the incidence of very slight individual hepatocellular necrosis with accompanying inflammation at 75 (2/4 mice at 2 or 7 days) or 150 mg/kg-day (3/4 mice at 2 days and 4/4 at 7 days). No treatment-related pathological findings were seen in male mice exposed at or below 15 mg/kg-day for 2 days and 1.5 mg/kg-day for 7 days.
Histopathology Observations: Female
Three of four females given 75 mg/kg-day PB for 2 days had treatment-related very slight centrilobular/midzonal hepatocyte hypertrophy with IE. All females given 150 mg/kg-day PB for 2 days had slight centrilobular/midzonal hepatocyte hypertrophy with IE. Females given 15, 75, or 150 mg/kg-day PB for 2 days had treatment-related increased incidence of hepatocytes in mitoses (3/4 mice in each dose group). Three of four females given 150 mg/kg-day for 7 days had increased hepatocyte mitotic figures that were interpreted to be treatment-related. A low incidence of increased mitotic figures (1/4) was observed in females given 15 and 75 mg/kg-day at 7 days. Treatmentrelated very slight increase in the individual hepatocyte necrosis with accompanying inflammation was noted in females given 75 (2/4 mice) or 150 mg/kg-day (1/4 mice) for 2 days. A dose-dependent increase in very slight hepatocellular necrosis with accompanying inflammation was noted in females given 75 (2/4 mice) or 150 mg/kg-day (4/4 mice) PB for 7 days. Necrosis of hepatocytes was also noted in one female given 15 mg/kg-day for 7 days. No histopathological effects were seen in control females or females receiving 0.15 mg/kg-day for 2 or 7 days.
qPCR Gene Expression and Enzyme Activity Analysis
A summary of qPCR gene expression results is presented in Table 1 . At 2 and 7 days, significantly elevated transcripts of Cyp1a1 were observed only in male mice at the highest dose of 150 mg/kg-day (2.0-and 2.2-fold). Evidence of CAR activation was reflected in significantly elevated Cyp2b10 transcripts at doses ≥ 15 mg/kg-day at 2 days (up to 522-fold), and at ≥ 1.5 mg/kg-day in males and ≥ 15 mg/kg-day at 7 days in females (up to 474-and 169-fold, respectively). The magnitude of Cyp2b10 transcript induction was roughly three times greater in males than females. Cyp3a11 transcripts were significantly elevated at 75 and 150 mg/kg-day in males (2.3-and 3.5-fold) and 150 mg/kg-day in females (2.3-fold) at 2 days and at 150 mg/kg-day in males (2.3-fold) and 1.5 and 150 mg/kg-day in females (2.0-and 3.2-fold respectively). No significant induction of the PPAR␣-related Cyp4a10 transcript levels were seen in either sex on either day; the non-dose-related decreases (up to −7.6-fold) following 7 days of exposure were not statistically significant (data not shown).
Significantly elevated Cyp1a2 was observed at 75 and 150 mg/kg-day in both sexes (from 2.0-to 3.6-fold) at 2 days and at 150 mg/kg-day (2.2-fold) in males and 75 and 150 mg/kg-day (2-5-and 3.6-fold respectively) in females at 7 days. PB is not believed to be an AhR agonist or inducer, nor are these results consistent with AhR inducers; however Cyp1a enzyme levels have been observed to increase following significant activation of CAR.
Liver Metabolic Enzyme Activities
Liver enzyme activity of Cyp1a (EROD), Cyp2b (PROD), and Cyp3a (BROD) are shown in Table 2 . Significantly elevated EROD activity (up to 4.4-fold) was seen at doses ≥ 15 mg/kgday in both sexes at 2 and 7 days. CAR-related enzyme activity was increased at ≥ 1.5 mg/kg-day for both genders at 2 days for both PROD (up to 8.6-fold) and BROD (up to 35.9-fold). At 7 days, PROD was significantly elevated at ≥ 1.5 mg/kg-day for both sexes (up to 11.5-fold) and BROD at ≥ 15 mg/kg-day in males (up to 39.5-fold) and ≥ 1.5 mg/kg-day in females (up to 8.5-fold). The magnitude of BROD induction in females decreased 6.4-fold from day 2 (35.9-fold) versus day 7 (5.6-fold), whereas it increased 3.3-fold in males (12.1 versus 39.5-fold, respectively).
Hepatocellular Proliferation
Hepatocellular proliferation was significantly increased at doses ≥ 15 mg/kg-day in males and ≥ 1.5 mg/kg-day in females at 2 days (Table 3 and Fig. 2 ). At 7 days, proliferation was significantly increased only at doses ≥ 75 mg/kg-day in males, whereas in females it was increased at ≥ 1.5 mg/kgday. Proliferation scores in males were roughly half that seen in females. Although females showed a greater degree of hepatocellular proliferation, liver weight gain was equivalent in both sexes.
Global Gene Expression
PCA was applied to investigate the expression data in a threedimensional space to reveal potential clusters within the experimental data on both the gene chip and treatment group level (Fig. 3) . Each gene chip profile (one gene chip per animal) of 48 males and 48 females was submitted for PCA using the most variable sequences (statistically filtered) to inspect the inherent grouping of male and female samples. The results shown in Figure 3 display a clear pattern of clustering by sex. This sex effect was further confirmed by performing a two-way ANOVA showing that sex was the biggest driver influencing the highest number of DEGs. Analysis at the treatment group level was conducted using ratios from 20 experimental groups (5 dose groups over 2 and 7 days for both male and female). Results are shown in Figure 4 with each dot representing a ratio experiment (treated/concurrent control) using the most variable sequences present on the gene chip. This analysis revealed an inherent dose-response structure with the lower and higher doses grouping together but distinct from each other with a transition at 15 mg/kg-day. A supervised statistical analysis using one-way ANOVA was performed to find DEGs between each treatment group and the concurrent control. Table 4 shows the pairwise data matrix with a trend of less than 100 DEGs for the 0.15, 1.5, and 15 mg/kgday doses and suggests that the no-observable transcriptional effect level (NOTEL) was 15 mg/kg-day for global gene expression in both sexes on both days. The 75 mg/kg-day dose marked a transition point from the 15 mg/kg-day dose where there was a 10-fold increase in the number of significant sequences for 2-day males and a corresponding 20-fold increase for the 7-day males compared with the 0.15 mg/kg-day dose. This trend was reciprocated in females at 2 and 7 days. The maximum number of significant sequences was observed in both sexes at the 150 mg/kg-day dose. These results were interpreted to represent a dose transitional point in the DEG analysis occurring at approximately 15 mg/kg-day, which is consistent with the PCA analysis shown in Figure 4 . The complexity of gene-gene interactions as a measure of transcriptional signaling is shown in Figures 5a and 5b for 2 and 7 days, respectively. Genes identified in the male groups began to show a modest level of interactions at 75 mg/kg-day with more gene interactions at 150 mg/kg-day. In contrast, females showed minimal interactions beginning at 15 and 75 mg/kg-day with a large increase of genes and interactions at 150 mg/kg-day (Fig. 5a ). Responses at day 7 showed a similar pattern as day 2 but with fewer gene-gene interactions. Female groups showed a response as low as 0.15 mg/kg-day (Fig. 5b) . These results are consistent with both the enzyme activity (PROD and BROD) assays which highlighted increased CAR activation at doses ≥ 1.5 mg/kg-day and increased hepatocellular proliferation at ≥ 15 mg/kg-day in males and ≥ 1.5 mg/kg-day in females with the increase in male proliferation index being half that seen in females. Genomic analyses further showed that Cyp2b10 was consistently induced across time and dose (Fig. 6 ) and was the most affected gene, consistent with qPCR results.
Classical Pathway Enrichment
The most significant canonical pathways identified from a classical de novo analysis of the genomic data included many redundant xenobiotic metabolism (CAR/PXR) and to a lesser extent cell-cycle and cellular stress response pathways (see Supplementary spreadsheets S1-S4). A focused analysis showed the greatest numbers of transcriptional effects were associated with sex > dose > time (Supplementary fig. 1 ). Cyp2b10 pathways were consistently the best indicator of exposure, with transcriptional responses being consistent with apical measures of cell proliferation and phase I enzyme induction (Fig.  6, Supplementary spreadsheet S5) . When the redundant de novo metabolic pathways were condensed, the most prominent canonical pathways identified by IPA analysis at 2 days in both sexes included phase I and II metabolism, cell-cycle and cellular stress pathways, such as protein ubiquitination (Figs. 7a and  b) . In addition, the Eif2 signaling pathway and the role of Brca1 in the DNA damage response were also identified as prominent pathways in females at 2 days. As mentioned previously and consistent with lower plasma PB at 7 days compared with 2 days suggesting metabolic adaptation, global gene expression and gene-gene interactions were attenuated at 7 days compared with 2 days (Table 4 and Fig. 5 ).
Transcriptional and apical benchmark dose-response analysis. BMD T and BMD A levels were estimated to describe po- tency in the low-dose region. The multiple low-dose levels, particularly when assessing global gene expression, facilitated low-dose extrapolation to approximate the doses below which changes in specific genes, cellular pathways, or apical effects could not be discerned from controls. BMD T levels for Cyp2b10 expression, considered a biomarker of CAR activation, were comparable between both sexes and time points based on the highest intensity probe (1451787 at). The Cyb2b10 BMD T were 16 and 11 mg/kg-day in males and females at 2 days, respectively, and 8 and 8 mg/kg-day in males and females at 7 days, respectively. Factoring in the fit of the dose-response curve, the lower 95% confidence interval BMDL T estimate was 6 mg/kgday at 2 and 7 days in both sexes. These BMD T /BMDL T estimates for Cyp2b10 are consistent with the NOTEL and lowestobservable transcriptional effect level (LOTEL) for Cyp2b10 of 1.5 and 15 mg/kg-day, respectively, based on the DEG lists for both sexes on both days.
Although the NOTEL was 15 mg/kg-day for global gene expression in both sexes on both days (Table 4) , pathway-level BMD T estimates (excluding redundant metabolic pathways as previously mentioned) suggested sex-and time-specific differences. Based on median BMD T estimates at 2 days, the doses required to activate two significant cell-cycle pathways, Cell Cycle Control of Chromosomal Replication, and Cell Cycle: G2/M DNA Damage Checkpoint Regulation, were comparable between each other and between the sexes (median BMD T of ∼50 mg/kg-day). However, median BMD T estimates for xenobiotic metabolism, PXR/RXR (retinoic acid receptor) activation, protein ubiquitination, Eif2 signaling, role of Brca1 in DNA damage, and glutathione-mediated detoxification pathways were approximately two-to fourfold lower in females (Table 5 ). These pathways were attenuated at 7 days based on higher median BMD T estimates and showed little sex-specific differences. Overall, the range of pathway BMD T estimates provides a more refined dose-response assessment compared with the global NOTEL of 15 mg/kg-day and LOTEL of 75 mg/kgday for global gene expression in the liver (Fig. 8) . BMD A estimates of the apical endpoints are summarized in Table 6 . In the low-dose region, BMD 1SD estimates suggest that PROD induction occurred at lower doses than BROD in both sexes and at lower doses in male compared with female mice. Of the dose-related apical liver effects, hepatocellular proliferation resulted in the lowest BMD 1SD estimates, which were more than an order of magnitude lower in females and progressed with time compared with males. The hepatocellular proliferation BMD 1SD values were 0.9 and 0.1 mg/kg-day in female mice fed PB for 2 and 7 days, respectively, compared with 13 and 14 mg/kg-day in male mice fed PB for 2 and 7 days, respectively. BMD A levels were not estimated for hepatic histopathology (hepatocellular hypertrophy, mitotic figures, or necrosis) due to the small sample size per dose group (n = 4). Unlike continuous data such as liver weight and cell proliferation for which the benchmark response is set to one control group SD, the minimum sample size to estimate a 10% effect level for incidence data that is within the power of detection is 10 (1 out of 10 animals affected).
Comparisons of BMD T and BMD A Estimates
The BMD estimates inform low-dose potency and enable a concordance analysis of key events at multiple levels of biological organization. BMD 1SD estimates for Cyp2B enzyme activity as measured via PROD, which ranged from 0.2-5 mg/kg-day, were lower than the BMD T for Cyp2b10 transcript levels, which ranged from 8-16 mg/kg-day. The variability of BMD 1SD estimates for Cyp2b10 quantified by qPCR (5-28 mg/kg-day) was attributed to standard deviation estimates approximated based on the range rule (maximum value − minimum value/4) because standard deviations for qPCR data are not calculated analogously to those used by the BMD models. Median BMD T estimates for DEG transcripts that mapped to the Mitotic Roles in Polo-like Kinases pathway was lower in males (44 mg/kgday) compared with females (74 mg/kg-day). Median BMD T estimates for other significant cell-cycle pathways were comparable between sexes (46-56 mg/kg-day; Table 5 ) and higher than BMD A estimates for hepatocellular proliferation, particularly in females (∼0.1-0.9 mg/kg-day). Thus, BrdU labeling was a more sensitive measure of hepatocellular proliferation compared with transcriptional analysis of cell-cycle pathways, most likely due to the additive nature of the proliferation endpoint versus the single point-in-time measure for gene expression. Table 7 is a high-level summary of multiple endpoints including gene expression, enzyme activity, gene-gene interactions, and key event measures such as hepatocyte hypertrophy, hepatocyte mitotic figures, and hepatocellular proliferation.
DISCUSSION
The current dose-response and time-course study establishes NOTEL, no-observable-adverse-effect level, and corresponding BMD T and BMD A levels for several key and associated events that have been proposed for a PB-induced liver tumor 436 GETER ET AL.
FIG. 4.
Principal component analysis using dose group ratios (treated vs. control) to depict a pattern of within group clustering and dose group separation in n-dimensional space. Note the dose groups distinctly separate from each other.
MOA. The key events include CAR activation commonly measured by altered CAR-specific gene expression, increased hepatocellular proliferation, formation of altered hepatic foci, and ultimately liver tumors (Cohen, 2010; Holsapple et al., 2006) . Altered epigenetic changes, induction of hepatic Cyp2b enzymes, liver hypertrophy, and decreased apoptosis have been identified as associative events (Elcombe et al., 2014) .
Higher tumor incidences are seen in male compared with female mice and rats following chronic PB exposure (Peraino et al., 1973; Rossi et al., 1977; Thorpe and Walker, 1973) and the contributing factors are not clearly understood. The lower plasma PB levels at ≥ 75 mg/kg-day in males and ≥ 15 mg/kgday in females at 7 days suggests an adaptive metabolic capacity compared with 2 days in both sexes (Fig. 1) , and the 1.5-fold higher plasma PB levels in males at ≥ 15 mg/kg-day compared with females suggests a greater metabolic/adaptive capacity in females. It is well known that the induction of CYP gene expression represents an adaptive response to protect against chemical exposure (Willson and Kliewer, 2002) and that the adaptive response takes 3-4 days to develop (Conney et al., 1960) . In the present study, the adaptive capacity is reflected in higher transcript abundance of Cyp2b10 in females at 7 days compared with 2 days, whereas higher transcript abundance of Cyp2c55 and Cyp2c65 was seen at 7 days in males. This increased metabolic capacity corresponded to globally decreased differential gene expression as well as gene-gene interactions at 7 days (Table 4 and Fig. 5) .
Although the elevated Cyp2b-and Cyp3a-associated transcripts, which correlated with induced PROD and BROD activity, respectively, in this study are typical following exposure to PB (Ueda et al., 2002) , one unexpected difference was seen in BROD activity between males and females. Comparing 2 and 7 days, BROD activity increased from 12.1-to 38.3-fold in males but decreased from 35.9-to 5.6-fold in females. Furthermore, PROD activity mildly increased at 7 days in males (from 8.4-to 10.1-fold) and mildly decreased in females (from 8.6-to 5.3-fold). Thus, both sexes had lower plasma PB levels after 7 days despite less metabolic activity in females.
Cyp2b10 expression is believed to be regulated by both male and female sex hormones, glucocorticoids (Nemoto and Sakurai, 1995) , and pituitary factors (Jarukamjorn et al., 2002) . Some studies report that Cyp2b10 is a female predominant liver cytochrome P450 with 3.6 times the endogenous transcript levels of males; Cyp3a11 was found to be sex independent (Renaud et al., 2011; Wiwi et al., 2004) . Furthermore, Cyp2b10 protein levels have been reported to be 75% higher in female C57BL/6 mice than males (Renaud et al., 2011) . A comparison of control qPCR Cyp2b10 Ct data between 2-and 7-day males and females showed only a modestly higher level of 2.4-or 1.3-fold, respectively, and is unlikely responsible for the magnitude of sex-related differences seen in the current study.
The pathway significance scores for "PXR/RXR Activation" were higher than for "Xenobiotic Metabolism" (Supplementary spreadsheets S1-S4) in males, recognizing that both pathways overlap with respect to nuclear receptor activation (CAR, PXR, AhR, and PPAR␣). Cyp2b10 was clearly the most potent Cyp isoform induced in both sexes on both days in terms of transcript abundance (fold change 35-100; Fig. 6 ), BMD T (8-16 mg/kg-day), and qPCR gene expression (Table 1) . Cyp3a5, a target gene of PXR activation, contributed to the PXR/RXR significance score only in males (fold change of 3-5 and BMD T = 77-105 mg/kg-day) consistent with qPCR data (Table 1) . AhR (fold change of 1.4 and BMD T = 81 mg/kg-day in females) or Cyp1a2 (fold change < 2 and BMD T = 15-19 mg/kg-day in both sexes) contributed to the pathway significance scores only at 2 days. PPAR␣ and/or Cyp4a transcription was repressed in both sexes in the present assessment, which is consistent with the low qPCR expression values for Cyp4a10 (data not shown).
FIG. 7.
(a)-(b) Selected significant cellular pathways altered according to sex after the redundant de novo metabolic pathways were condensed. This figure highlights a more prominent cellular stress response in females compared with males in which metabolic pathways predominate. This figure was generated by mapping DEGs in Ingenuity Pathway Knowledgebase.
FIG. 8. (a)-(b)
The range of transcriptional BMD levels (mg/kg-day) for selected pathways significantly altered in both sexes at 2 days. Corresponding values at 7 days were attenuated and thus not shown. Horizontal hatched lines define the 15 mg/kg-day NOTEL and 75 mg/kg-day LOTEL.
These results suggest that CAR is the primary nuclear receptor mediating early liver effects in CD-1 mice exposed to PB.
Nuclear receptor activation can exert a direct hyperplastic effect on the rodent liver by stimulating hepatocyte proliferation ) and significant increases in hepatocytes can be observed within 7 days of PB exposure (Peraino et al., 1971) , concentrated in the centrilobular region (Kolaja et al., 1996) . Recently, Zheng et al., (2011) assigned a LOTEL of 10 mg/kg-day for liver gene expression in male mice receiving PB via gavage for 3 days based on the ob- servation that only a few genes were significantly altered out of the 1300 present on the HC ToxArray. The authors concluded that transcriptional changes were more sensitive than conventional apical measures; however, hepatocellular proliferation (as measured by BrdU) was not evaluated in that study. In the current study, hepatocellular proliferation was equally induced in the three hepatic zones in both sexes. At 2 days, female mice were more sensitive to the mitogenic effects of PB, inducing significant hepatocellular proliferation in all liver zones at 1.5 mg/kg-day, whereas only the midzonal region was affected in males. The difference in proliferation was more pronounced at 7 days with females retaining elevated levels in all liver zones at ≥ 1.5 mg/kg-day and males affected only at ≥ 75 mg/kg-day. The proliferation index in males was roughly half that seen in females and this key event was the most sensitive apical effect based on BMD estimates. The higher proliferative activity in female CD-1 mice compared with males reported for the CAR agonist TCPOBOP has been attributed to increased hepatic levels of cyclin D1, cyclin A, E2F, and higher mRNA levels of Cyp2b10 in females and to partial inhibition of CAR-related activity by testosterone metabolites in males. Thus, the sex difference in proliferation is likely more biologically complex than what can be deduced using only a corollary biomarker such as altered Cyp2b10 mRNA levels.
The AhR is a ligand-activated transcription factor involved in the regulation of several genes, including those for xenobioticmetabolizing enzymes such as cytochrome P450 Cyp1a1/2 (Nebert, 2000) . AhR activators include some polycyclic aro- matic hydrocarbons, such as chlorinated dioxins and related halogenated aromatic hydrocarbons. In a study examining the effects of 3-methylcholanthrene (a prototypical AhR agonist) exposure to mice, EROD activity was elevated 19.5-fold (Sugihara et al., 2008) . A significant dose-dependent increase in AhR-related EROD activity was seen in the current study with a maximum increase of 4.4-fold in females exposed to 150 mg/kg-day PB for 2 days. It has been suggested that increased EROD activity observed following exposure to CAR inducers is only seen after a significant induction of Cyp2b enzyme (Corcos et al., 1998) , which is consistent with the significant PROD (CAR-related) and EROD induction seen at ≥ 1.5 and 15 mg/kg-day PB, respectively, in this study. The magnitude of EROD induction was also consistently lower than the increase in PROD or BROD, and that reported for a known AhR inducer. Cyp1a1 transcription was not altered in females in the current study despite a significant increase in Cyp1a2 transcript and EROD levels. In mice, Cyp1a2 was reported to be a PBinducible gene not regulated by AhR (Sakuma et al., 1999) . Thus, Cyp1a2 and EROD induction in the current study may be more attributable to CAR-rather than AhR-dependent activation. Liver Cyp4a10 mRNA levels were examined in the current study to address PPAR␣ activation (Aldridge et al., 1995) , which has been associated with regulation of lipid metabolism, glucose homeostasis, cellular differentiation, inflammation, and cancer (Chinetti et al., 2000; Desvergne and Wahli, 1999; Duval et al., 2002) . In mice exposed to the prototypical PPAR␣ inducers WY-14643 and clofibrate, Cyp4a10 transcripts were induced 6.2-and 4.6-fold, respectively (Takeuchi et al., 2006; Wang et al., 2008) . In rats exposed to clofibrate for 4 days, Cyp4a1 mRNA was elevated 18-fold (Konig et al., 2007) . However, PB appears to slightly suppress PPAR␣-related gene and enzyme activity in both rats (80 mg/kg-day I.P. for 3 days) and mice (100 mg/kg-day I.P. single dose) (Baldwin et al., 2006; Ueda et al., 2002; Wang et al., 2008) . In the current study, Cyp4a10 transcription was not significantly altered, however a slight decrease in males at all doses except 150 mg/kg-day was seen at 7 days (data not shown).
PB has been reported to reduce concentrations of the thyroid hormone thyroxine (T 4 ) in rodents (Hood et al., 1999 (Hood et al., , 2003 Liu et al., 1995) due to increased metabolism by glucuronidation and sulfation (Robbins, 1981) . Sustained hepatic glucuronyltransferase and sulfotransferase activity can produce a cascade effect of lower serum T 4 , increased thyroid stimulating hormone (TSH), and elevated thyroid follicular cell proliferation that can eventually result in thyroid tumors (Barter and Klaassen, 1992; Dellarco et al., 2006; Hurley, 1998) . Of the 10 glucuronyltransferase and 13 sulfotransferase genes assessed in the microarray data, only Sult1e1 had a dose-related increase in female mice at ≥ 15 mg/kg-day (shown in Supplementary spreadsheet S6). Male mice had dose-related changes in Sult1c2, Sult1e1, Sult3a1, and Ugt2b37 at ≥ 75 mg/kg-day suggesting that male mice have a less sensitive, but more involved and diverse transcriptional response versus females and that the induction of these genes occurred at a dose above that required for CAR (Table 6) . Although global expression profiling has clear utility in chemical risk assessment (Edwards and Preston, 2008) , microarrays often sacrifice specificity for scale (Troyanskaya, 2005) . For example, it has recently been reported that PB indirectly activates CAR by inhibiting the epidermal growth factor receptor (EGFR) signaling pathway, altering target genes such as Rack1 and Gadd45b (Mutoh et al., 2013) . Canonical pathways involving EGFR signaling were not prominent in the present assessment. The most significant EGFR-related pathway (−log p value of 3.84) was Hepatic Fibrosis/Hepatic Stellate Cell Activation in males at 7 days and Rack1 or Gadd45b did not contribute to the significance score.
Beyond the mapping of DEGs to cellular pathways, the current study is the first to use BMD modeling to discern sexspecific differences in early key events involved in PB-induced liver effects. An advantage of the present study design for doseresponse modeling and low-dose extrapolation was the inclusion of multiple doses below (0.15, 1.5, and 15 mg/kg-day), at (75 mg/kg-day), and above (150 mg/kg-day) the NOEL and tumorigenic dose of 10 and 75 mg/kg-day, respectively, in CD-1 mice fed PB for two years (Whysner et al., 1996) . Notably, the NOTEL and LOTEL for global gene expression (15 and 75 mg/kg-day, respectively) in both sexes at both 2 and 7 days are consistent with these previously reported chronic effect levels.
One of the extrapolation assumptions inherent in the use of chronic rodent bioassay data to predict carcinogenic potential in humans is that high-dose responses in rodents are relevant at exposure doses which are orders of magnitude lower (Cohen and Ellwein, 1992) . PB is a prototypical nongenotoxic carcinogen in which a threshold dose-response approach can be employed in quantitative cancer risk assessment when supported by MOA information based on the assumption that the adverse outcome (i.e., cancer) will not occur if exposure concentrations are below levels that do not alter tumorigenic key events. When consistent with apical effects, transcriptional changes in genes and pathways can also serve as quantitative "bioindicators" of treatment-related adverse responses (Preston, 2002) . Given the fivefold dose spacing between the NOTEL and LOTEL, our pathway-level BMD T estimates may provide more informative dose estimates of pathway activation. Based on median BMD T estimates, phase I and II metabolism and cellular stress pathways were activated at two-to fourfold lower doses in females compared with males at 2 days (Table  6 ). The enhanced ability to remove damaged proteins though Eif2 signaling or ubiquitination and to respond to DNA damage through Brca1 signaling combined with a greater CAR/PXRmediated metabolism and glutathione-mediated detoxification capacity in females could ultimately contribute to a lower susceptibility to tumor formation. Given the clear sex-specific differences in cell proliferation measured via BrdU, it is interesting that only one of the three prominent cell-cycle pathways, the Mitotic Roles of Polo-like Kinases pathway, showed sex-specific differences in BMD T estimates at 2 days (Table 6 ) with median BMD T estimates suggesting activation at lower doses in males (44 mg/kg-day) compared with females (74 mg/kg-day). Because male mice are ultimately more susceptible to PB-induced tumor formation, the cell-cycle pathways reported here may be more reflective of PB's ability to exert CAR/PXR-mediated effects on the cell cycle compared with more general, albeit more sensitive BrdU measurements. Although sex-specific potency differences in the Mitotic Roles of Polo-like Kinases pathway were identified at 2 days, it is difficult to propose which cell-cycle pathway(s) may ultimately contribute to liver tumor development given that the prominent cell-cycle pathways at 2 days were attenuated at 7 days in the present assessment. Further, liver cancer is known to be promoted by testosterone (Kemp and Drinkwater, 1989) and inhibited by ovarian hormones (Poole and Drinkwater, 1996) . Recognizing the potency differences in BrdU response as counterintuitive to females ultimately having a lower liver tumor occurrence, the study duration of only 7 days may be a factor along with the interplay of modulating factors such as epigenetic changes (Phillips and Goodman, 2009) , altered gap junction intercellular communications (Chipman et al., 2003) , or altered regulation of apoptosis (Bursch et al., 2005) .
In conclusion, the results from this study identified low-dose transitions for apical and molecular endpoints which are consistent with the tumorigenic response to PB in rodents. To our knowledge, this is the first study to comprehensively characterize multiple key apical and molecular endpoints below, at, and above the PB carcinogenic dose and to estimate potency in the low-dose region with BMD modeling. Being consistent with the known tumorigenic response of PB, our results also have utility when conducting quantitative risk assessments of CAR-mediated hepatocarcinogenesis.
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